Novo Nordisk is exploring a direct listing on the New York Stock Exchange to replace current American depositary receipts and boost its US profile. CEO Mike Doustdar confirmed the potential move durin
Novo Nordisk faces investor pressure to diversify beyond its blockbuster weight-loss drugs amid rising competition from Eli Lilly and impending semaglutide patent expiries. Analysts suggest acquisitio
Novo Nordisk has partnered with Anthropic to integrate Claude AI models into its R&D workflows for accelerated drug discovery. The collaboration aims to shorten research timelines and improve scientif
Novo Nordisk launched its oral Wegovy weight-loss pill in Germany following EU approval, intensifying competition with Eli Lilly in the expanding GLP-1 market. This semaglutide-based treatment targets
Novo Nordisk shares climbed 35% as its oral Wegovy competes strongly against Eli Lilly's Zepbound in the projected $100 billion obesity market. Investors await Q2 results to assess the durability of t
Novo Nordisk launched its once-weekly basal insulin Awiqli in India to treat type 1 and 2 diabetes. The product reduces injection frequency to 52 times yearly, competing in a market projected to reach
Cyber extortion group FulcrumSec claims to have stolen over a terabyte of data from Novo Nordisk, including drug trial information and production facility details, after demanding a $25 million ransom
Novo Nordisk plans to seek Chinese regulatory approval for its oral Wegovy pill very soon, CEO Mike Doustdar said. The company aims to compete with Eli Lilly in China's rapidly expanding GLP-1 market,
Novo Nordisk confirmed a cyberattack where unauthorized copies of patient data from certain clinical trials were taken. While core operations remain unaffected, the company has launched an investigati
Driven by AI productivity, global companies are shifting core functions to in-house India hubs, with Novo Nordisk expanding its role in drug launch preparations.
Novo Nordisk reported a first-quarter operating profit of $5.16 billion, surpassing forecasts amidst intensifying competition with Eli Lilly in the obesity drug market. The company aims to recover fro
Novo Nordisk announced its oral GLP-1 drug successfully met the primary endpoint in a late-stage study involving children and adolescents aged 10 to 17 with type 2 diabetes.
Novo Nordisk partners with OpenAI to deploy AI across drug discovery, manufacturing, and supply chains. The move aims to boost efficiency and competitiveness in the lucrative weight-loss drug market,
Novo Nordisk has partnered with Vivtex Corporation to license oral drug-delivery technologies for weight loss and diabetes, agreeing to pay up to $2.1 billion in milestone payments.
ChemBrief